Aisling Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Aisling Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3M	Hold	434,455	–	–	0.49%	10
2026 Q1	$1.63M	Hold	434,455	–	–	0.34%	11
2025 Q4	$1.31M	Hold	434,455	–	–	0.27%	11
2025 Q3	$825K	Hold	434,455	–	–	0.18%	12
2025 Q2	$617K	Hold	434,455	–	–	0.17%	11
2025 Q1	$665K	Hold	434,455	–	–	0.23%	11
2024 Q4	$1.08M	Hold	434,455	–	–	0.38%	12
2024 Q3	$500K	Hold	434,455	–	–	0.19%	15
2024 Q2	$478K	Hold	434,455	–	–	0.21%	14
2024 Q1	$539K	Hold	434,455	–	–	0.18%	15
2023 Q4	$456K	Hold	434,455	–	–	0.14%	14
2023 Q3	$2.98M	Hold	434,455	–	–	1.23%	9
2023 Q2	$4.51M	Hold	434,455	–	–	2.21%	8
2023 Q1	$3.51M	Hold	434,455	–	–	1.69%	9
2022 Q4	$6.84M	Sell	434,455 -200,000	-32%	-$3.22M	4.52%	5
2022 Q3	$9.99M	Hold	634,455	–	–	6.63%	5
2022 Q2	$8.86M	Hold	634,455	–	–	6.32%	5
2022 Q1	$10.9M	Hold	634,455	–	–	5.9%	6
2021 Q4	$9.22M	Hold	634,455	–	–	3.25%	8
2021 Q3	$11.4M	Hold	634,455	–	–	2.28%	8
2021 Q2	$11.1M	Hold	634,455	–	–	1.78%	10
2021 Q1	$16M	Hold	634,455	–	–	2.88%	6
2020 Q4	$4.11M	Hold	634,455	–	–	0.7%	11
2020 Q3	$1.63M	Hold	634,455	–	–	0.52%	13
2020 Q2	$1.03M	Hold	634,455	–	–	0.39%	13
2020 Q1	$660K	Hold	634,455	–	–	0.29%	14
2019 Q4	$1.2M	Hold	634,455	–	–	0.46%	13
2019 Q3	$685K	Hold	634,455	–	–	0.36%	13
2019 Q2	$1.39M	Hold	634,455	–	–	0.59%	14
2019 Q1	$3.8M	Hold	634,455	–	–	2.89%	11
2018 Q4	$4.69M	Buy	+634,455	New	+$6.54M	4.94%	8

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Aisling Capital Management's ACRS Position: Q2 2026 in Review

Aisling Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 434,455 shares worth $2.3M. The position accounts for 0.49% of the portfolio, ranked #10.

Aisling Capital Management first reported a position in ACRS in Q4 2018 and has held it in 31 quarters since. The position peaked at $16M in Q1 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Aisling Capital Management held 434,455 shares of Aclaris Therapeutics worth $2.3M as of Q2 2026.
Aisling Capital Management left its Aclaris Therapeutics share count unchanged in Q2 2026.
Aclaris Therapeutics made up 0.49% of Aisling Capital Management's portfolio in Q2 2026, its #10 holding.
Aisling Capital Management first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 31 quarters since.
Aisling Capital Management's Aclaris Therapeutics position peaked at $16M in Q1 2021.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.